You just read:

Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

May 03, 2019, 07:30 ET